SUMMARY OF
KEY
BENEFITS AND
RISKS OF
MEDICATIONS
Benefits are classified according to major effects on fasting glucose, postprandial glucose, The intensity of the background shading of the cells reflects relative importance of the bene
Metformin (MET)
Postprandial Glucose (PPG) - lowering
Fasting glucose (FPG) - lowering
Nonalcoholic fatty liver disease (NAFLD)
Hypoglycemia
Gastrointestinal Symptoms
Risk of use with renal insufficiency
Contraindicated in Liver Failure or Predisposition to Lactic Acidosis
Heart failure / Edema
Weight Gain Fractures
Drug-Drug interactions
Inhibitor DPP4
GLP-1 Agonist (Incretin Mimetic)
Mild Moderate Mild Neutral
Sulfonylurea (SU)
MEDICA Glinide**
BENE
Moderate Moderate to Marked Moderate Moderate
Mild Neutral Neutral Mild Mild Neutral Moderate Neutral Moderate Severe Severe
Use with caution in CHF
Benefit Neutral Neutral
Reduce Dosage Moderate
Neutral Neutral
Neutral Neutral Neutral
Neutral Neutral
Benefit Neutral Neutral
* The abbreviations used here correspond to those used on the algorithm. **The term 'glinide' includes both repaglinide and nateglinide.
Moderate Neutral
Moderate Neutral
Moderate Mild Neutral RIS Mild Neutral Neutral Moderate Moderate Neutral Mild Neutral Neutral Mild Neutral Moderate Moderate
